Bioabsorbable Stents (BAS) - Medical Devices Pipeline Assessment, 2018

  • ID: 4577087
  • Report
  • 154 pages
  • GlobalData
1 of 4

FEATURED COMPANIES

  • 480 Biomedical Inc
  • Biosten, LLC
  • Cardionovum GmbH
  • MicroPort Scientific Corp
  • Northwestern University
  • S3V Vascular Technologies
  • MORE
Bioabsorbable Stents (BAS) - Medical Devices Pipeline Assessment, 2018

Summary

The author's Medical Devices sector report, “Bioabsorbable Stents (BAS) - Medical Devices Pipeline Assessment, 2018" provides an overview of Bioabsorbable Stents (BAS) currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Bioabsorbable Stents (BAS) pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by the author's team of industry experts.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope
  • Extensive coverage of the Bioabsorbable Stents (BAS) under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Bioabsorbable Stents (BAS) and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved/Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment/industry
Reasons to buy

The report enables you to:
  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of Bioabsorbable Stents (BAS) under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product’s current stage of development, territory and estimated launch date
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • 480 Biomedical Inc
  • Biosten, LLC
  • Cardionovum GmbH
  • MicroPort Scientific Corp
  • Northwestern University
  • S3V Vascular Technologies
  • MORE
1 Table of Contents

2 Introduction
2.1 Bioabsorbable Stents (BAS) Overview

3 Products under Development
3.1 Bioabsorbable Stents (BAS) - Pipeline Products by Stage of Development
3.2 Bioabsorbable Stents (BAS) - Pipeline Products by Territory
3.3 Bioabsorbable Stents (BAS) - Pipeline Products by Regulatory Path
3.4 Bioabsorbable Stents (BAS) - Pipeline Products by Estimated Approval Date
3.5 Bioabsorbable Stents (BAS) - Ongoing Clinical Trials

4 Bioabsorbable Stents (BAS) - Pipeline Products under Development by Companies
4.1 Bioabsorbable Stents (BAS) Companies - Pipeline Products by Stage of Development
4.2 Bioabsorbable Stents (BAS) - Pipeline Products by Stage of Development

5 Bioabsorbable Stents (BAS) Companies and Product Overview
5.1 480 Biomedical Inc Company Overview
5.2 Abbott Vascular Inc Company Overview
5.3 Amaranth Medical Inc Company Overview
5.4 Arterius Ltd Company Overview
5.5 Biosensors International Group Ltd Company Overview
5.6 Biosten, LLC Company Overview
5.7 Biotronik AG Company Overview
5.8 Biotronik SE & Co KG Company Overview
5.9 Boston Scientific Corp Company Overview
5.10 Cardionovum GmbH Company Overview
5.11 Cordis Corp Company Overview
5.12 HangZhou HuaAn Biotechnology Co., Ltd. Company Overview
5.13 Icon Interventional Systems, Inc. Company Overview
5.14 Japan Stent Technology Co., Ltd. Company Overview
5.15 Kyoto Medical Planning Co Ltd Company Overview
5.16 Lepu Medical Technology (Beijing) Co Ltd Company Overview
5.17 Lifetech Scientific (Shenzhen) Co Ltd Company Overview
5.18 Manli Cardiology Ltd Company Overview
5.19 Meril Life Sciences Pvt Ltd Company Overview
5.20 Micell Technologies Inc Company Overview
5.21 Michigan Technological University Company Overview
5.22 MicroPort Scientific Corp Company Overview
5.23 Minvasys SAS Company Overview
5.24 MIV Therapeutics Inc Company Overview
5.25 NanoCoeur, Inc. Company Overview
5.26 North Carolina State University Company Overview
5.27 Northwestern University Company Overview
5.28 OrbusNeich Company Overview
5.29 Pediastent LLC Company Overview
5.30 QualiMed Innovative Medizinprodukte GmbH Company Overview
5.31 REVA Medical Inc Company Overview
5.32 S3V Vascular Technologies Company Overview
5.33 Shanghai MicroPort Medical Group Co Ltd Company Overview
5.34 Tepha Inc Company Overview
5.35 University of Alabama at Birmingham Company Overview
5.36 University of Florida Company Overview
5.37 VasoTech Inc. Company Overview
5.38 Xenogenics Corporation Company Overview

6 Bioabsorbable Stents (BAS) - Recent Developments
6.1 May 24, 2018: Reva Symposium Showcases Clinical Data
6.2 May 23, 2018: Fantom’s Positive Two-Year Results Show Sustained Safety and Efficacy
6.3 May 23, 2018: Positive Two-Year Data from MiStent DESSOLVE III Trial Presented at EuroPCR - Excellent Safety And Low Target Lesion Revascularization (TLR) Rates Persist
6.4 May 23, 2018: Amaranth Presented Interim Nine-Month Follow-up MAGNITUDE (98 micron) and Two-Year Follow-up APTITUDE (115 micron) Data at EuroPCR Symposium
6.5 May 23, 2018: Fantom’s Positive Two-Year Results Show Sustained Safety and Efficacy
6.6 May 17, 2018: Mr. Jonathan Chen Promoted to Chief International Business Officer of MPSC
6.7 May 16, 2018: Reva Announces First Implant Of The Fantom Bioresorbable Scaffold In Turkey
6.8 May 11, 2018: Terumo Appoints its U.S.-based Subsidiary's Associate as the Fifth Terumo Fellow
6.9 May 09, 2018: Reva Medical Announces First Quarter 2018 Financial Results
6.10 Apr 25, 2018: Boston Scientific Reports Financial Results For First Quarter 2018
6.11 Apr 25, 2018: Xianjian Technology Receives the Most Attention from Institutional Investors
6.12 Apr 16, 2018: REVA to Present Full Two-Year FANTOM II Data at EuroPCR
6.13 Apr 02, 2018: REVA Initiates Commercial Distribution Partnership in Turkey
6.14 Mar 28, 2018: MicroPort Scientific Announces 2017 Annual Results
6.15 Mar 27, 2018: REVA Announces First Implant of the Fantom Encore Bioresorbable Scaffold in Switzerland
6.16 Mar 27, 2018: MicroPort Scientific Announces Year Ended 31 December 2017 Financial Results
6.17 Mar 20, 2018: Micell Technologies Announces Expanded Patent Estate
6.18 Mar 08, 2018: REVA Medical Reports Fourth Quarter and Full Year 2017 Financial Results
6.19 Mar 01, 2018: GTX Launches $99.00 Easy Start Plan for GPS SmartSole and Economy Service Plan as low as $14.95
6.20 Mar 01, 2018: Study finds the best stent for treatment following a heart attack
6.21 Feb 26, 2018: Reva Announces CE Mark And First Implant Of The Fantom Encore Bioresorbable Scaffold
6.22 Feb 08, 2018: Terumo Revises the Full-Year Results Forecast for FY 2017
6.23 Feb 08, 2018: MicroPort Signs Strategic Agreement with Neptunus Biotechnology
6.24 Feb 05, 2018: Reva Appoints Stephen Oesterle As Board Of Directors
6.25 Feb 01, 2018: REVA Medical: Quarter Ended 31 December 2017
6.26 Feb 01, 2018: Boston Scientific Announces Results for Fourth Quarter and Full Year 2017
6.27 Jan 25, 2018: REVA Announces First Implant of the Fantom Bioresorbable Scaffold in Italy
6.28 Jan 25, 2018: Terumo Announces Change of Directors and Executive Officers
6.29 Jan 09, 2018: Positive Five-Year Data Published for MiStent in EuroIntervention
6.30 Jan 09, 2018: MicroPort Selected as 2017 China Innovative Medical Device Company
6.31 Jan 09, 2018: MicroPort Awarded 2017 Shanghai Pilot Enterprise with Outstanding Innovation
6.32 Jan 09, 2018: Boston Scientific Announces Preliminary Unaudited Sales For The Fourth Quarter And Full Year Ended December 31, 2017
6.33 Jan 07, 2018: LifeTech Scientific and Ally Bridge Group Form China-Global Medtech Investment and Operating Partnership

7 Appendix
7.1 Methodology
7.2 About
7.3 Contact
7.4 Disclaimer

List of Tables
Table 1: Bioabsorbable Stents (BAS) - Pipeline Products by Stage of Development
Table 2: Bioabsorbable Stents (BAS) - Pipeline Products by Territory
Table 3: Bioabsorbable Stents (BAS) - Pipeline Products by Regulatory Path
Table 4: Bioabsorbable Stents (BAS) - Pipeline Products by Estimated Approval Date
Table 5: Bioabsorbable Stents (BAS) - Ongoing Clinical Trials
Table 6: Bioabsorbable Stents (BAS) Companies - Pipeline Products by Stage of Development
Table 7: Bioabsorbable Stents (BAS) - Pipeline Products by Stage of Development
Table 8: 480 Biomedical Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 9: Absorbable Scaffold Stent - Neonatal Aortic Coarctation - Product Status
Table 10: Absorbable Scaffold Stent - Neonatal Aortic Coarctation - Product Description
Table 11: Abbott Vascular Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 12: Second Generation Bioresorbable Vascular Scaffold - Product Status
Table 13: Second Generation Bioresorbable Vascular Scaffold - Product Description
Table 14: Amaranth Medical Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 15: 80-micron MAGNITUDE Bioresorbable Scaffold - Product Status
Table 16: 80-micron MAGNITUDE Bioresorbable Scaffold - Product Description
Table 17: APTITUDE Sirolimus-Eluting Bioresorbable Scaffold - Product Status
Table 18: APTITUDE Sirolimus-Eluting Bioresorbable Scaffold - Product Description
Table 19: FORTITUDE Scaffold - Product Status
Table 20: FORTITUDE Scaffold - Product Description
Table 21: MAGNITUDE Sirolimus-Eluting Bioresorbable Scaffold - Product Status
Table 22: MAGNITUDE Sirolimus-Eluting Bioresorbable Scaffold - Product Description
Table 23: Second Generation FORTITUDE Scaffold - Product Status
Table 24: Second Generation FORTITUDE Scaffold - Product Description
Table 25: Amaranth Medical Inc - Ongoing Clinical Trials Overview
Table 26: FORTITUDE Scaffold - Amaranth Endovascular Study of a Drug-eluting Bioresorbable Coronary Scaffold
Table 27: FORTITUDE Scaffold - Restoring Endoluminal Narrowing Using Bioresorbable Scaffolds - European Trial
Table 28: APTITUDE Sirolimus-Eluting Bioresorbable Scaffold - Restoring Endoluminal Narrowing Using Bioresorbable Scaffolds - Extended Trial II
Table 29: MAGNITUDE Sirolimus-Eluting Bioresorbable Scaffold - Restoring Endoluminal Narrowing Using Bioresorbable Scaffolds - Extended Trial III
Table 30: Arterius Ltd Pipeline Products & Ongoing Clinical Trials Overview
Table 31: Arteriosorb Absorbable Drug-Eluting Scaffold - Product Status
Table 32: Arteriosorb Absorbable Drug-Eluting Scaffold - Product Description
Table 33: Biosensors International Group Ltd Pipeline Products & Ongoing Clinical Trials Overview
Table 34: Sparrow Drug Eluting Stent System - Product Status
Table 35: Sparrow Drug Eluting Stent System - Product Description
Table 36: Biosten, LLC Pipeline Products & Ongoing Clinical Trials Overview
Table 37: Biodegradable Endovascular Implant - Product Status
Table 38: Biodegradable Endovascular Implant - Product Description
Table 39: Biotronik AG Pipeline Products & Ongoing Clinical Trials Overview
Table 40: Magmaris Bioresorbable Magnesium Scaffold - Product Status
Table 41: Magmaris Bioresorbable Magnesium Scaffold - Product Description
Table 42: Biotronik AG - Ongoing Clinical Trials Overview
Table 43: Magmaris Bioresorbable Magnesium Scaffold - A Sirolimus Eluting Bioresorbable Magnesium Stent for Treatment of Coronary Bifurcation Lesions: The BIFSORB Pilot Study II
Table 44: Magmaris Bioresorbable Magnesium Scaffold - BIOTRONIK - Safety and Clinical Performance of the Drug Eluting Absorbable Metal Scaffold (DREAMS 2nd Generation) in the Treatment of Subjects with de Novo Lesions in Native Coronary Arteries: BIOSOLVE-II
Table 45: Magmaris Bioresorbable Magnesium Scaffold - BIOTRONIKS - Acute Performance of a Drug Eluting Absorbable Metal Scaffold (DREAMS 2G) in Patients with de Novo Lesions in Native Coronary Arteries: BIOSOLVE-III
Table 46: Magmaris Bioresorbable Magnesium Scaffold - Biotroniks - Safety and Performance in de Novo Lesion of Native Coronary Arteries with Magmaris- Registry: BIOSOLVE-IV
Table 47: Magmaris Bioresorbable Magnesium Scaffold - Coronary Artery Healing Process after Bioresorbable Scaffold in Patients with Non-ST-segment Elevation Myocardial Infarction (NSTEMI)
Table 48: Magmaris Bioresorbable Magnesium Scaffold - Magnesium-based Bioresorbable Scaffold and Vasomotor Function in Patients with Acute ST Segment Elevation Myocardial Infarction
Table 49: Magmaris Bioresorbable Magnesium Scaffold - Optical Coherence Tomography Evaluation of Bioabsorbable Vascular Scaffold Technique with Magmaris
Table 50: Magmaris Bioresorbable Magnesium Scaffold - Prospective Observational Registry of Patients with a Bioabsorbable Magnesium Stent Implant -MAGMARIS- in Usual Clinical Practice
Table 51: Magmaris Bioresorbable Magnesium Scaffold - Scaffold Implantation in Emilia-Romagna
Table 52: Biotronik SE & Co KG Pipeline Products & Ongoing Clinical Trials Overview
Table 53: AMS-2 - Product Status
Table 54: AMS-2 - Product Description
Table 55: Boston Scientific Corp Pipeline Products & Ongoing Clinical Trials Overview
Table 56: Fully Resorbable Drug-Eluting Scaffold System - Product Status
Table 57: Fully Resorbable Drug-Eluting Scaffold System - Product Description
Table 58: Next Generation SYNERGY - Product Status
Table 59: Next Generation SYNERGY - Product Description
Table 60: Boston Scientific Corp - Ongoing Clinical Trials Overview
Table 61: Fully Resorbable Drug-Eluting Scaffold System - Fully Absorbable Scaffold Feasibility Study
Table 62: Cardionovum GmbH Pipeline Products & Ongoing Clinical Trials Overview
Table 63: CARDIOSORB - Product Status
Table 64: CARDIOSORB - Product Description
Table 65: Cordis Corp Pipeline Products & Ongoing Clinical Trials Overview
Table 66: SymBio Pimecrolimus/Paclitaxel-eluting Stent - Product Status
Table 67: SymBio Pimecrolimus/Paclitaxel-eluting Stent - Product Description
Table 68: HangZhou HuaAn Biotechnology Co., Ltd. Pipeline Products & Ongoing Clinical Trials Overview
Table 69: Xinsorb BRS - Product Status
Table 70: Xinsorb BRS - Product Description
Table 71: Icon Interventional Systems, Inc. Pipeline Products & Ongoing Clinical Trials Overview
Table 72: Biosorb Pediatric Dissolving Stent - Product Status
Table 73: Biosorb Pediatric Dissolving Stent - Product Description
Table 74: Japan Stent Technology Co., Ltd. Pipeline Products & Ongoing Clinical Trials Overview
Table 75: Bioabsorbable Stent - Product Status
Table 76: Bioabsorbable Stent - Product Description
Table 77: Kyoto Medical Planning Co Ltd Pipeline Products & Ongoing Clinical Trials Overview
Table 78: Igaki-Tamai Coronary Stent - Product Status
Table 79: Igaki-Tamai Coronary Stent - Product Description
Table 80: Lepu Medical Technology (Beijing) Co Ltd Pipeline Products & Ongoing Clinical Trials Overview
Table 81: NeoVas Bioresorbable Coronary Scaffold (BCS) - Product Status
Table 82: NeoVas Bioresorbable Coronary Scaffold (BCS) - Product Description
Table 83: Lepu Medical Technology (Beijing) Co Ltd - Ongoing Clinical Trials Overview
Table 84: NeoVas Bioresorbable Coronary Scaffold (BCS) - Clinical Evaluation of a Bioresorbable Sirolimus-eluting Coronary Scaffold in the Treatment of Patients with de Novo Coronary Artery Lesion (NeoVas): a Single Arm Registry Study
Table 85: NeoVas Bioresorbable Coronary Scaffold (BCS) - Clinical Evaluation of a Bioresorbable Sirolimus-eluting Coronary Scaffold in the Treatment of Patients with Denovo Coronary Artery Lesion (NeoVas): Randomized Controlled Trial
Table 86: Lifetech Scientific (Shenzhen) Co Ltd Pipeline Products & Ongoing Clinical Trials Overview
Table 87: Iron-based Drug-eluting Bioresorbable Coronary Scaffold System - Product Status
Table 88: Iron-based Drug-eluting Bioresorbable Coronary Scaffold System - Product Description
Table 89: Lifetech Scientific (Shenzhen) Co Ltd - Ongoing Clinical Trials Overview
Table 90: Iron-based Drug-eluting Bioresorbable Coronary Scaffold System - A First-in-man Study of Sirolimus-eluting Iron Bioresorbable Coronary Scaffold System (IBS)
Table 91: Manli Cardiology Ltd Pipeline Products & Ongoing Clinical Trials Overview
Table 92: MIRAGE - Product Status
Table 93: MIRAGE - Product Description
Table 94: Meril Life Sciences Pvt Ltd Pipeline Products & Ongoing Clinical Trials Overview
Table 95: BioMime - Product Status
Table 96: BioMime - Product Description
Table 97: BIOMIME AURA - Product Status
Table 98: BIOMIME AURA - Product Description
Table 99: Meril Life Sciences Pvt Ltd - Ongoing Clinical Trials Overview
Table 100: BioMime - A Prospective, Active Control, Open-label, Multi-center, Randomized Clinical trial comparing BioMime Branch - Sirolimus Eluting Coronary Side Branch Stent System Versus Xience family of Everolimus Eluting Coronary Stent System to Evaluate Safety and Performance in Patients with de Novo Coronary Bifurcation Lesions
Table 101: BioMime - A Prospective, Single-arm, Multi-center, Observational, Real World Registry to Evaluate Safety and Performance of the BioMime Morph Sirolimus Eluting Coronary Stent System for Very Long Coronary Lesions.
Table 102: BioMime - Biomime Biosorbable Polymer Sirolimus-eluting Stent in All-comers Patients Treated with Percutaneous Coronary Interventions: The BELLINI Registry
Table 103: BioMime - Randomized Study to Evaluate Segmental Late Loss Comparing Two PCI Strategies Using a Long Stent Versus 2 Shorter Stents to Treat Long or Tandem Coronary Stenosis
Table 104: BioMime - Real World Drug-eluting Stent Prospective, Open, Multi-site, Registry in Korea: BioMime Stent, Ultimaster Stent Versus Xience Stent by SMart Angioplastry Research Team: SMARTDESK-MX
Table 105: BIOMIME AURA - A Prospective, Active Control, Open-label, Multi-center, Randomized Clinical trial comparing BioMime Branch - Sirolimus Eluting Coronary Side Branch Stent System Versus Xience family of Everolimus Eluting Coronary Stent System to Evaluate Safety and Performance in Patients with de Novo Coronary Bifurcation Lesions
Table 106: BIOMIME AURA - Randomized Study to Evaluate Segmental Late Loss Comparing Two PCI Strategies Using a Long Stent Versus 2 Shorter Stents to Treat Long or Tandem Coronary Stenosis
Table 107: Micell Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 108: Bioresorbable Scaffold (BRS) - Product Status
Table 109: Bioresorbable Scaffold (BRS) - Product Description
Table 110: MiStent SES - Product Status
Table 111: MiStent SES - Product Description
Table 112: Micell Technologies Inc - Ongoing Clinical Trials Overview
Table 113: MiStent SES - A Prospective, Single-blinded, Multi-center, Randomized, Controlled, Registered Clinical Trial on the Efficacy and Safety of Sirolimus-eluting Stent (MiStent System) in the Treatment of Patients with Coronary Heart Disease
Table 114: MiStent SES - MiStent Sirolimus Eluting Absorbable Polymer Coronary Stent System (MiStent SES) Optical Coherence Tomography (OCT)
Table 115: MiStent SES - Multicenter Randomized Study of the MiStent Sirolimus Eluting Absorbable Polymer Stent System (MiStent SES) for Revascularization of Coronary Arteries
Table 116: MiStent SES - Multicenter Randomized Study of the Mistent Sirolimus Eluting Absorbable Polymer Stent System (MT005) for Revascularization of Coronary Arteries
Table 117: Michigan Technological University Pipeline Products & Ongoing Clinical Trials Overview
Table 118: Bioabsorbable Stent - Product Status
Table 119: Bioabsorbable Stent - Product Description
Table 120: MicroPort Scientific Corp Pipeline Products & Ongoing Clinical Trials Overview
Table 121: Firefalcon Bioresorbable Device - Product Status
Table 122: Firefalcon Bioresorbable Device - Product Description
Table 123: Minvasys SAS Pipeline Products & Ongoing Clinical Trials Overview
Table 124: Nile LM SIR Sirolimus Eluting Intracoronary Stent - Product Status
Table 125: Nile LM SIR Sirolimus Eluting Intracoronary Stent - Product Description
Table 126: MIV Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 127: Smart-1 DES - Product Status
Table 128: Smart-1 DES - Product Description
Table 129: Smart-4 DES - Product Status
Table 130: Smart-4 DES - Product Description

List of Figures
Figure 1: Bioabsorbable Stents (BAS) - Pipeline Products by Stage of Development
Figure 2: Bioabsorbable Stents (BAS) - Pipeline Products by Territory
Figure 3: Bioabsorbable Stents (BAS) - Pipeline Products by Regulatory Path
Figure 4: Bioabsorbable Stents (BAS) - Pipeline Products by Estimated Approval Date
Figure 5: Bioabsorbable Stents (BAS) - Ongoing Clinical Trials
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • 480 Biomedical Inc
  • Abbott Vascular Inc
  • Amaranth Medical Inc
  • Arterius Ltd
  • Biosensors International Group Ltd
  • Biosten, LLC
  • Biotronik AG
  • Biotronik SE & Co KG
  • Boston Scientific Corp
  • Cardionovum GmbH
  • Cordis Corp
  • HangZhou HuaAn Biotechnology Co., Ltd.
  • Icon Interventional Systems, Inc.
  • Japan Stent Technology Co., Ltd.
  • Kyoto Medical Planning Co Ltd
  • Lepu Medical Technology (Beijing) Co Ltd
  • Lifetech Scientific (Shenzhen) Co Ltd
  • Manli Cardiology Ltd
  • Meril Life Sciences Pvt Ltd
  • Micell Technologies Inc
  • Michigan Technological University
  • MicroPort Scientific Corp
  • Minvasys SAS
  • MIV Therapeutics Inc
  • NanoCoeur, Inc.
  • North Carolina State University
  • Northwestern University
  • OrbusNeich
  • Pediastent LLC
  • QualiMed Innovative Medizinprodukte GmbH
  • REVA Medical Inc
  • S3V Vascular Technologies
  • Shanghai MicroPort Medical Group Co Ltd
  • Tepha Inc
  • University of Alabama at Birmingham
  • University of Florida
  • VasoTech Inc.
  • Xenogenics Corporation
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll